154 related articles for article (PubMed ID: 20978105)
21. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
22. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
Bittner B; Riek M; Holmes B; Grange S
Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
[TBL] [Abstract][Full Text] [Related]
23. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
Shibata N; Gao W; Okamoto H; Kishida T; Iwasaki K; Yoshikawa Y; Takada K
J Pharm Sci; 2002 Mar; 91(3):680-9. PubMed ID: 11920753
[TBL] [Abstract][Full Text] [Related]
24. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
25. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
[TBL] [Abstract][Full Text] [Related]
26. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
la Porte CJ; Li Y; Béïque L; Foster BC; Chauhan B; Garber GE; Cameron DW; van Heeswijk RP
Clin Pharmacol Ther; 2007 Oct; 82(4):389-95. PubMed ID: 17361121
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
28. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
[TBL] [Abstract][Full Text] [Related]
29. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
32. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.
Pathak SM; Musmade P; Dengle S; Karthik A; Bhat K; Udupa N
Eur J Pharm Sci; 2010 Nov; 41(3-4):440-51. PubMed ID: 20656025
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations.
Buchanan CM; Buchanan NL; Edgar KJ; Little JL; Ramsey MG; Ruble KM; Wacher VJ; Wempe MF
Biomacromolecules; 2008 Jan; 9(1):305-13. PubMed ID: 18072746
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
Shin HS; Bae SK; Lee MG
Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145
[TBL] [Abstract][Full Text] [Related]
35. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
36. In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats.
Catalán-Latorre A; Nácher A; Merino V; Jiménez-Torres NV; Merino-Sanjuán M
Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):245-52. PubMed ID: 21535410
[TBL] [Abstract][Full Text] [Related]
37. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS; Ananworanich J; Apateerapong W; Sankote J; Hill A; Hirschel B; Cooper D; Lange J; Phanuphak P; Ruxrungtham K; Burger D
J Antimicrob Chemother; 2004 Oct; 54(4):785-90. PubMed ID: 15329366
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.
Shibata N; Kageyama M; Kimura K; Tadano J; Hukushima H; Namiki H; Yoshikawa Y; Takada K
Biol Pharm Bull; 2004 Feb; 27(2):203-9. PubMed ID: 14758034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]